News >

Improved Patient Selection Needed to Optimize Expanding Options in Bladder Cancer

Gina Columbus @ginacolumbusonc
Published: Friday, Oct 27, 2017

Jean Hoffman-Censits, MD

Jean Hoffman-Censits, MD
As the pipeline of bladder cancer continues to expand and researchers investigate targeted therapies, vaccines, antibody-drug conjugates, and checkpoint inhibitors alone and in combination, a major question that remains is which patients will achieve responses to these various agents.

® State of the Science SummitTM on Renal Cell Carcinoma and Bladder Cancer.

OncLive: What is the current state of bladder cancer?

Hoffman-Censits: We have 2 different indications for immunotherapy. One is in the refractory state, so in patients who have metastatic urothelial cancer and have had recurrent disease within 12 months of getting cisplatin, and then whose who are not candidates for cisplatin. Both of those indications are standard-of-care indications that we give immunotherapy for. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication